SEC Filings
Haemonetics Lifts Revenue Outlook To 8% To 11% Growth, Cuts Margin Expansion Target
The plasma and blood-technology maker raised its sales forecast but now sees 0 to 50 basis points of margin expansion, down from 50 to 100.
Haemonetics (HAE) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The plasma and blood-technology maker raised its sales forecast but now sees 0 to 50 basis points of margin expansion, down from 50 to 100.
Earnings
Haemonetics is leaving fiscal 2027 guidance unchanged and will size the supply deal's impact on its November earnings call.